Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China.

Zhao FH, Jeronimo J, Qiao YL, Schweizer J, Chen W, Valdez M, Lu P, Zhang X, Kang LN, Bansil P, Paul P, Mahoney C, Berard-Bergery M, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE.

Cancer Prev Res (Phila). 2013 Sep;6(9):938-48. doi: 10.1158/1940-6207.CAPR-13-0091.

2.

Lower cost strategies for triage of human papillomavirus DNA-positive women.

Qiao YL, Jeronimo J, Zhao FH, Schweizer J, Chen W, Valdez M, Lu P, Zhang X, Kang LN, Bansil P, Paul P, Mahoney C, Berard-Bergery M, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE.

Int J Cancer. 2014 Jun 15;134(12):2891-901. doi: 10.1002/ijc.28616.

3.

Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.

Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, Booth C, Pérez AG, Chávez-Avilés MN, Belinson J.

Int J Gynecol Cancer. 2013 Mar;23(3):513-8. doi: 10.1097/IGC.0b013e318280f3bc.

PMID:
23334437
4.

A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China.

Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, Chen F, Pan QJ, Lorincz AT.

Lancet Oncol. 2008 Oct;9(10):929-36. doi: 10.1016/S1470-2045(08)70210-9.

PMID:
18805733
5.

Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.

Shi JF, Canfell K, Lew JB, Zhao FH, Legood R, Ning Y, Simonella L, Ma L, Kang YJ, Zhang YZ, Smith MA, Chen JF, Feng XX, Qiao YL.

BMC Cancer. 2011 Jun 13;11:239. doi: 10.1186/1471-2407-11-239.

6.

Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china.

Valdez M, Jeronimo J, Bansil P, Qiao YL, Zhao FH, Chen W, Zhang X, Kang LN, Paul P, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE.

Int J Cancer. 2016 Mar 15;138(6):1453-61. doi: 10.1002/ijc.29877.

PMID:
26421807
7.

Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.

Zhao FH, Lewkowitz AK, Chen F, Lin MJ, Hu SY, Zhang X, Pan QJ, Ma JF, Niyazi M, Li CQ, Li SM, Smith JS, Belinson JL, Qiao YL, Castle PE.

J Natl Cancer Inst. 2012 Feb 8;104(3):178-88. doi: 10.1093/jnci/djr532.

8.

Clinical determinants of a positive visual inspection after treatment with acetic acid for cervical cancer screening.

Castle PE, Qiao YL, Zhao FH, Chen W, Valdez M, Zhang X, Kang LN, Bansil P, Paul P, Bai P, Peck R, Li J, Chen F, Jeronimo J.

BJOG. 2014 May;121(6):739-46. doi: 10.1111/1471-0528.12646.

9.

The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens.

Chen W, Jeronimo J, Zhao FH, Qiao YL, Valdez M, Zhang X, Kang LN, Bansil P, Paul P, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE.

J Clin Virol. 2014 Dec;61(4):553-7. doi: 10.1016/j.jcv.2014.09.018.

PMID:
25453572
10.

The Influence of Human Papillomavirus Genotypes on Visual Screening and Diagnosis of Cervical Precancer and Cancer.

Jeronimo J, Bansil P, Valdez M, Kang LN, Zhao FH, Qiao YL, Chen W, Zhang X, Paul P, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE.

J Low Genit Tract Dis. 2015 Jul;19(3):220-3. doi: 10.1097/LGT.0000000000000088.

PMID:
25279978
11.

Optimal positive cutoff points for careHPV testing of clinician- and self-collected specimens in primary cervical cancer screening: an analysis from rural China.

Kang LN, Jeronimo J, Qiao YL, Zhao FH, Chen W, Valdez M, Zhang X, Bansil P, Paul P, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE.

J Clin Microbiol. 2014 Jun;52(6):1954-61. doi: 10.1128/JCM.03432-13.

12.

[Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment].

Zhao FH, Chen JF, Gao XH, Gao LM, Liu QG, Liu ZH, Xu H, Ma JF, Ma L, Xu XL, Hu SY, Ning Y, Shi JF, Qiao YL.

Zhonghua Zhong Liu Za Zhi. 2012 Aug;34(8):632-6. doi: 10.3760/cma.j.issn.0253-3766.2012.08.017. Chinese.

PMID:
23159002
13.

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.

J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9.

14.

Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.

Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao FH, Hillemanns P, Anttila A.

Lancet Oncol. 2014 Feb;15(2):172-83. doi: 10.1016/S1470-2045(13)70570-9. Review.

PMID:
24433684
15.

The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.

Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE; New Mexico HPV Pap Registry Steering Committee..

Int J Cancer. 2014 Aug 1;135(3):624-34. doi: 10.1002/ijc.28605.

16.

Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: Implications for vaginal self-collection.

Belinson JL, Hu S, Niyazi M, Pretorius RG, Wang H, Wen C, Smith JS, Li J, Taddeo FJ, Burchette RJ, Qiao YL.

Int J Cancer. 2010 Sep 1;127(5):1151-7. doi: 10.1002/ijc.25144.

17.
18.

Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.

Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, Buckland J, Rydzak G, Lorincz AT, Wacholder S.

J Clin Oncol. 2012 Sep 1;30(25):3044-50. doi: 10.1200/JCO.2011.38.8389.

19.

Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer.

Castle PE, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Wacholder S, Burk RD, Manos MM, Schussler JE, Macomber P, Schiffman M.

J Clin Microbiol. 2003 Sep;41(9):4022-30.

20.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444.

Items per page

Supplemental Content

Support Center